Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ULTIMATE I: Ublituximab vs Teriflunomide in Relapsing Multiple Sclerosis
2017-000638-75Phase 3Unknown
- Sponsor
- TG Therapeutics, Inc.
- Start
- Sep 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ublituximab in multiple sclerosis (MS) (2 arms), sponsored by TG Therapeutics, Inc. Primary endpoint: Annualized Relapse Rate (ARR). Status: unknown.
02
Drugs
ublituximab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2017-000638-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000638-75.